AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02448836 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham: dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil
Description: Patients will undergo 8 sessions of Sham dTMS treatment for two weeks (4 sessions every week).
Study NCT04971616 — intervention group
Intervention type: OTHER
Intervention: Demographic data and range of motion.
Description: The body parameters (BMI, age, gender), daily activities (daily steps, sedentary), work and rest time (sleep time, quality) were collected through wearable devices. The range of motion of neck and waist was collected through hand-held devices.
Study NCT02171364 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual ablation in based 3D CT of patient who diagnosed AF
Study NCT02171364 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional ablation based on physician's personal experience
Study NCT03751540 — intervention group
Intervention type: PROCEDURE
Intervention: ostap
Description: this block is performed under general anesthesia in this patients for postoperative analgesia.
Study NCT03751540 — intervention group
Intervention type: PROCEDURE
Intervention: SIPB plus rectus sheath block
Description: this block is performed under general anesthesia in this patients for postoperative analgesia.
Study NCT02991859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (ELLIPTA or DISKUS)
Description: Lactose dry powder inhaler will be administered using ELLIPTA or DISKUS for both treatment periods.
Study NCT01171937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: children get randomized to either placebo or active risperidone
Study NCT01171937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children get randomized to either placebo or risperidone
Study NCT03674450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback Training
Description: The study will utilize the Physiolab GP8 heart rate variability and respiration system on a laptop computer used solely for the study with the proper security passwords to protect participant information. The equipment consists of two electrocardiogram sensors (one per wrist) attached by sports wrist bands, a respiration monitoring belt placed around the upper abdomen, two galvanic skin conductance sensors attached to the fingertips, and a thermistor sensor attached to one of the finger tips. Participants will perform a series of monitored breathing exercises.
Study NCT04217057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-DOTA-ECL1i
Description: Will be produced by the Cyclotron Facility at Washington University School of Medicine
Study NCT02096965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Patients will receive daily dose of 45 mg (30 mg at 8 AM and 15 mg at 4 PM).
Study NCT02096965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will receive daily dose at 8 AM and at 4 PM.
Study NCT00042835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00042835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00042835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT00042835 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study NCT00042835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00042835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00042835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT03757169 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hand grip isometric contraction
Description: The patients at the Hand Grip group will perform 12 weeks of hand grip exercises, three times/week for 16 minutes with time to rest.
Study NCT03757169 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The patients will receive verbal orientations about the OSA and the arterial hypertension.
Study NCT00906295 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allowed drop in hemoglobin to 4.5-5.5 mmol/L
Description: Transfusion with red blood cells to hemoglobin between 4.5-5.5 mmol/L (Transfusion threshold of 4.5 mmol/L)
Study NCT00906295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L
Description: Transfusion with red blood cells to between hemoglobin 5.6-6.5 mmol/L (Transfusion threshold of 5.5 mmol/L)
Study NCT01153542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-770
Description: In period 1, subjects will receive a single oral dose of desipramine on Day 1.
Study NCT01153542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-770
Description: In period 2, subjects will receive 150 mg VX-770 q12h orally from the morning of Day 1 through the evening of Day 9. Subjects will receive 50 mg Desipramine as a single dose on Day 5 of period 2.
Study NCT03938324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PiCASO Intervention Group
Description: This mobile health intervention utilizes an established telephone/text based secure interface to allow AYAs access knowledge, experience, and instrumental/emotional support from a trained peer coach who has already developed independence an active self-manager. Peers with shared experiences provide instrumental (e.g., health maintenance skills) and emotional support that likely lead to improvements in quality of life. Involving peers in supporting AYAs with chronic conditions to promote self-management and patient activation disrupts the typical over-reliance on the parent and health care provider that often impedes developing independence.
Study NCT03938324 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Attention Control Group
Description: Over 12 months the attention control group participants will receive a monthly electronic newsletter with educational content about childhood onset chronic condition management and the differences between pediatric and adult health care systems, as well as a monthly phone call from study staff to ensure receipt of the newsletter and to answer questions regarding content, and an opportunity to link them to other resources. If participants report health concerns they will be directed to contact their health care team.
Study NCT04146207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: SHR0302 po QD
Study NCT04146207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 1mg/kg/d po
Study NCT00042835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04635020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iStent
Description: 2 trabecular Stent injected at the end of the cataract surgery to the trabecular meshwork
Study NCT04635020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLT-laser
Description: 1 month after cataract surgery laser treatment to the trabecular meshwork (100 applications, 360 degrees)
Study NCT04635020 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Conventional cataract surgery
Study NCT04635020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Conventional cataract surgery
Study NCT02022306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TD-6450
Study NCT02022306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TD-6450
Study NCT02022306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04070898 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remove urinary catheter after surgery
Description: Remove bladder catheter after surgery
Study NCT03259841 — intervention group
Intervention type: OTHER
Intervention: Ultrasound assessment of gastric contet
Description: Ultrasound assessment of gastric content is performed in fasted patient undergoing cholecystectomy.
Study NCT05526313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilinostat Mesylate 1.2mg/m2
Description: 1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Study NCT05526313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilinostat Mesylate 2.4mg/m2
Description: 1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Study NCT05526313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilinostat Mesylate 4.0mg/m2
Description: 1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Study NCT05526313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilinostat Mesylate 6.0mg/m2
Description: 1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Study NCT05526313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilinostat Mesylate 8.4mg/m2
Description: 1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Study NCT05526313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilinostat Mesylate 11.2mg/m2
Description: 1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Study NCT05526313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilinostat Mesylate 15mg/m2
Description: 1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Study NCT04292496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Introperative leak testing
Description: After anastomosis was completed. We test the integrity of anastomosis intraoperatively.
Study NCT04044248 — intervention group
Intervention type: DEVICE
Intervention: TIPS-obliteration
Description: Transjugular intrahepatic portosystemic shunt (TIPS) decompression of portal hypertension coupled with transvenous obliteration of gastric varices (GVs).
Study NCT03808467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: Nine individual transdiagnostic CRT sessions will be delivered once per week, each session lasting approximately 45 minutes. Building on previously published CRT manuals for anorexia nervosa and obesity, a transdiagnostic CRT manual developed for this project will be used during the course of CRT treatment. The manual comprises an introduction to CRT for eating disorders, and a detailed nine-session structure incorporating cognitive and behavioral tasks in the following domains; (1) planning-impulsivity, (2) flexibility-rigidity and (3) central coherence-attention to details. A certain set of guiding questions will accompany each task with the aim of stimulating metacognition (i.e. thinking about thinking).
Study NCT03808467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: According to Norwegian guidelines established by the Norwegian Directorate of Health, the patients are likely to receive treatment focusing directly on the ED symptomatology, i.e normalization of weight in the case of underweight, reduction of binging and purging and normalization of other ED related thoughts and behaviors. Since both in-patients, patients in day treatment and out-patients will be included in the study, the number of hours with therapeutic interventions will vary. Records of the participants' received number of therapeutic hours will be logged weekly during the intervention for participants in both arms of the study.
Study NCT03808467 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: According to Norwegian guidelines established by the Norwegian Directorate of Health, the patients are likely to receive treatment focusing directly on the ED symptomatology, i.e normalization of weight in the case of underweight, reduction of binging and purging and normalization of other ED related thoughts and behaviors. Since both in-patients, patients in day treatment and out-patients will be included in the study, the number of hours with therapeutic interventions will vary. Records of the participants' received number of therapeutic hours will be logged weekly during the intervention for participants in both arms of the study.
Study NCT03528642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01807143 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03528642 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study NCT03528642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaglenastat Hydrochloride
Description: Given PO
Study NCT03528642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT02635672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIP152 (BAY 1251152)
Description: The starting dose of Cohort 1 will be 5 mg IV (30 minute infusion) fixed dose once weekly (5 mg/week) for 21 day cycles.
Study NCT02635672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIP152 (BAY 1251152) 30 mg
Description: 30 mg IV (30 minute infusion) fixed dose once weekly of a 21 day cycle.
Study NCT02635672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keytruda
Description: 200 mg IV fixed dose once every 3 weeks of a 21 day cycle
Study NCT02635672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIP152 (BAY 1251152) 15 mg
Description: The starting dose of Cohort 3 will be 15 mg IV (30 minute infusion) fixed dose once weekly (15 mg/week) for 21 day cycles.
Study NCT03294954 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GINAKIT Cells
Description: Six dose levels of GINAKIT cells will be studied. Dosing will be based on the actual number of transduced cells. All doses are per m2.~* Dose Level 1 = 3 x 10\^6~* Dose Level 2 = 1 x 10\^7~* Dose Level 3 = 3 x 10\^7~* Dose Level 4 = 1 x 10\^8~* Dose Level 5 = 3 x 10\^8~* Dose Level 6 = 1 x 10\^9
Study NCT03294954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GINAKIT cells + Etanercept
Description: At the time of the amendment version 13.0, we have treated 6 patients on DL4 without DLT. With Etanercept, we plan to start from DL4. Three dose levels of GINAKIT cells in combination of Etanercept will be studied. Dosing will be based on the actual number of transduced cells. All doses are per m2.~* Combination Dose level 4 = 1 x 108 + Etanercept~* Combination Dose level 5 = 3 x 108 + Etanercept~* Combination Dose level 6 = 1 x 109 + Etanercept
Study NCT04295759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB7839
Description: INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years).
Study NCT04011189 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Videotaping
Description: Before the videotaping, patients will be asked on their baseline pain scores. Their face and body pose from a frontal view will be videotaped via a mobile phone with no internet access. The collected videos will be further processed to extract key points, which will be the primary input for modelling algorithms and will further ensure anonymity of the patients in the video sequences.
Study NCT04011189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients will be asked to fill in 1-2 questionnaires before surgery/procedure/consultation (Hospital Anxiety and Depression Scale (HADS) and/or EQ-5D-3L). After surgery/procedure/consultation, patients will be again asked to fill in HADS questionnaire (optional).~For pediatrics patient, only Child Pain Anxiety Symptoms Scale (CPASS) will be administered before the surgery.
Study NCT04011189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Empatica E4 wristband
Description: A medical grade wearable device, Empatica E4 wristband, will be used in phase 3 for pediatrics patients to monitor real-time physiological data on heart rate and body temperature.
Study NCT01270997 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks
Study NCT01270997 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks
Study NCT03554161 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Description: Patients with refractory BD associated uveitis will receive Tocilizumab therapy, the efficacy and corticosteroids-tapering effects will be evaluated.
Study NCT03434301 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReliaTack™
Description: Absorbable tack (ReliaTack™) to fixate Symbotex™ composite mesh in the elective repair of incisional hernia.
Study NCT03434301 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Protack™
Description: Non-absorbable tack (Protack™) to fixate Symbotex™ composite mesh in the elective repair of incisional hernia.
Study NCT05250583 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LV-Visio-AMTRIX
Description: Chemically-treated, viro-inactivated, freeze-dried and irradiated allograft placed by the investigator during patients' hospital visit
Study NCT04040231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Galinpepimut-S
Description: Galinpepimut-S will be administered alone on weeks 0 and 2. Participants will receive the galinpepimut-S vaccine and nivolumab over 16 weeks in the initial treatment phase.
Study NCT04040231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive nivolumab and the galinpepimut-S vaccine over 16 weeks in the initial treatment phase.
Study NCT04040231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: All participants will receive Sargramostim (GM-CSF) 70 mcg injected subcutaneously on days 0 and -2 of each cycle
Study NCT04105634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FNOS
Description: The imaging drug used for this group is called 18F-NOS, it is an experimental imaging drug that has not yet been approved by the Food and Drug Administration (FDA) for use except in a research study. Subject will not receive the results or feedback from the study participation, the images may be reviewed with subject or her/his doctor upon request but will not be used to make decisions about subject medical care.
Study NCT02291289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500 mg/m\^2 via IV infusion on Day 1 of every 2-week cycle
Study NCT02291289 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cetuximab
Description: 500 mg/m\^2 via IV infusion on Day 1 of every 2-week cycle
Study NCT02291289 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FOLFOX induction regimen
Description: Administered per the Investigator's discretion in accordance with locally approved prescribing information.
Study NCT02291289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoropyrimidine (5-FU/LV or capecitabine)
Description: Per Investigator's discretion: 5-FU 1600-2400 mg/m\^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m\^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.
Study NCT02291289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine (5-FU/LV or capecitabine)
Description: Per Investigator's discretion: 5-FU 1600-2400 mg/m\^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m\^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.
Study NCT04105634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetaben
Description: The imaging drug used for this group is called Florbetaben, it is an FDA approved radioactive PET tracer used to image amyloid plaques in the body. Although not yet FDA approved for this purpose, it has already been used clinically to image amyloid in other parts of the body. Subject will not receive the results or feedback from the study participation, the images may be reviewed with subject or her/his doctor upon request but will not be used to make decisions about subject medical care.
Study NCT00167531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treadmill walking with partial weight support
Study NCT02291289 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluoropyrimidine (5-FU/LV or capecitabine)
Description: Per Investigator's discretion: 5-FU 1600-2400 mg/m\^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m\^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.
Study NCT02291289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle, or a fixed dose of 840 mg